RT Journal Article
SR Electronic
T1 Evaluation of the Family Liaison Officer (FLO) role during the COVID-19 Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.18.21256801
DO 10.1101/2021.05.18.21256801
A1 Hughes, Luke
A1 Anderton, Lisa
A1 Taylor, Rachel M
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.05.18.21256801.abstract
AB Objectives During the first wave of COVID-19 heavy restrictions were placed on hospital visitations in the United Kingdom. To support communication between families and patients a central London hospital introduced the role of the Family Liaison Officer. Communication within healthcare settings is often the subject of contention, particularly for patient’s families. During periods of crisis communication can become strained for patients and their families. We aimed to evaluate the rapid implementation of this role to provide guidance if it was required in the future and to explore the potential for this to become a standard role.Design Service evaluationSetting Single National Health Service hospital in London.Methods Semi-structured video interviews with a convenience sample of 12 participants. Data were analysed using Framework Analysis.Participants Family Liaison Officers (n=5) and colleagues who experienced working alongside them (n=7).Results Key themes were identified from the interviews pertaining to the role, the team, the impact and the future. Two versions of the role emerged though the process based on the Family Liaison Officer’s previous background: Clinical Family Liaison Officers (primarily nurses) and Pastoral Family Liaison Officers (primarily play specialists). Both the Family Liaison Officers and their colleagues agreed that the role had a very positive impact on the wards during this time. Negative aspects of the role, such as a lack of induction, boundaries or clear structure were also discussed.Conclusion The Family Liaison Officer was a key role during the pandemic in facilitating communication between patient, clinical team and family. The challenges associated with the role reflect the speed in which it was implemented but it was evident to those in the role and clinicians who the role was supporting that it has potential to help improve hospital communication, and the work of healthcare staff outside of a pandemic.Strengths and limitations of this studyThis was an in-depth evaluation of the Family Liaison Officer role from the perspective of those in the role and the clinical team who they were providing support.The sample included representation of the different disciplines who worked in the FLO role.The evaluation only represents the professional perspective and not the experience of the family.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was given for this evaluation. The hospital supported LH to conduct the study, RMT is funded through UCLH Charity and is a National Institute for Health Research (NIHR) Senior Nurse Research Leader. The views expressed in this article are those of the author and not necessarily those of UCLH Charity, NIHR, or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLH/UCL Joint Research Office classed your studies as service evaluation and deemed approvals by Health Research Authority or NHS REC to be not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data are available.